Moderna Boosts Revenue Guidance on Strong Vaccine Sales

Moderna has upgraded its revenue outlook following better-than-expected sales of its Covid-19 vaccine. The biotechnology firm's revised guidance reflects sustained market demand for its immunization products. This positive financial update highlights the ongoing commercial viability of the company's core vaccine portfolio. Investors and market analysts have responded favorably to the strengthened revenue forecast.